FDA OKs Vertex Pharma's CF combo med Symdeko

|About: Vertex Pharmaceuticals... (VRTX)|By:, SA News Editor

The FDA approves Vertex Pharmaceuticals' (NASDAQ:VRTX) SYMDEKO (tezacaftor/ivacaftor and ivacaftor) for cystic fibrosis (CF) patients at least 12 years old who have two copies of the F508del mutation in the CFTR gene or who have at least one mutation that is responsive to tezacaftor/ivacaftor.

It is the company's third CF medication approved in the U.S.

Subscribe for full text news in your inbox